Health Catalyst (NASDAQ:HCAT) reported Q3 CY2025 revenue of $76.32 million, beating analyst estimates by 1.7%. Adjusted EPS was $0.06, in line with expectations. However, revenue guidance for Q4 is $73.5 million, below analyst estimates. Operating margin decreased to -22.9%. Market capitalization is $199.2 million. CEO Dan Burton expressed satisfaction with the financial results.

Health Catalyst provides data analytics technology for healthcare organizations, focusing on measurable outcomes. While the company showed 12% annual sales growth over five years, recent trends indicate slowing demand with a 4.4% revenue growth rate in the last two years. Analysts expect a 7.7% sales decline next quarter and a 3.9% decline over the next 12 months.

Despite exceeding EBITDA expectations, Health Catalyst’s revenue guidance for next quarter missed estimates. The stock rose 1.6% post-earnings. The company’s CAC payback period was negative, indicating inefficient customer acquisition efforts. Analysts question the company’s long-term growth potential and suggest considering quality and valuation before investing.

Read more at Yahoo Finance: Health Catalyst (NASDAQ:HCAT) Posts Better-Than-Expected Sales In Q3